A biotechnology company that focuses on drug discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines.

Moderna, Inc.

A biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

BioNTech SE

A research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.

CRISPR Therapeutics AG

A clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

Agenus Inc.

A biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.

Adaptive Biotechnologies Corporation

A biotechnology company that focuses on developing potentially transformative gene therapies for severe genetic and rare diseases.

bluebird bio, Inc.

A leading genome editing company that aims to translate its genome editing technology into a novel class of human therapeutics for the treatment of genetic diseases.

Editas Medicine, Inc.

A leading genome editing company focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system.

Intellia Therapeutics, Inc.

A biotechnology company that develops precision genetic medicines through base editing.

Beam Therapeutics Inc.

Bolt Biotherapeutics is a biotechnology company that develops the Boltbody™ platform, utilizing systemically delivered Immune-Stimulating Antibody Conjugates (ISAC) to convert cold tumors into immunologically hot tumors, effectively eliminating them in preclinical models.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University.  The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Genmab

Vivo Capital

Rock Springs Capital

Samsara BioCapital

Sofinnova Investments

Surveyor Capital

Novo Holdings

Pfizer Venture Investments

Pivotal bioVenture Partners

RA Capital Management

Bolt Biotherapeutics, Inc. 

#BoltBio management will be in New York for the Guggenheim Partners Healthcare Talks Biotech Conference. We look forward to connecting in person!

Today is #WorldCancerDay, and members of #TeamBolt are running in support of The DONNA Foundation and its Fight to FINISH #BreastCancer. Learn more about the DONNA Foundation here: https://bit.ly/4b5oMaJ

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about The DONNA Foundation and their work to FINISH #breastcancer: https://bit.ly/48PVsUk 

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

NASDAQ:BOLT

Bolt Biotherapeutics

Last Close

0.74

26/07 20:00

Market Cap

27.47M

Beta: 0.99

Volume Today

138.00K

Avg: 250.78K

PE Ratio

−0.60

PFCF: −0.56